Review article : New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease
© 2024 John Wiley & Sons Ltd..
BACKGROUND: Alpha-1 antitrypsin liver disease (AATLD) occurs in a subset of patients with alpha-1 antitrypsin deficiency. Risk factors for disease progression and specific pathophysiologic features are not well known and validated non-invasive assessments for disease severity are lacking. Currently, there are no approved treatments for AATLD.
AIMS: To outline existing understanding of AATLD and to identify knowledge gaps critical to improving clinical trial design and development of new treatments.
METHODS: This report was developed following a multi-stakeholder forum organised by the Alpha-1 Antitrypsin Deficiency Related Liver Disease Expert Panel in which experts presented an overview of the available literature on this topic.
RESULTS: AATLD results from a 'gain of toxic function' and primarily manifests in those with the homozygous Pi*ZZ genotype. Accumulation of misfolded 'Z' AAT protein in liver cells triggers intracellular hepatocyte injury which may ultimately lead to hepatic fibrosis. Male gender, age over 50 years, persistently elevated liver tests, concomitant hepatitis B or C virus infection, and metabolic syndrome, including obesity and type 2 diabetes mellitus, are known risk factors for adult AATLD. While the gold standard for assessing AATLD disease activity is liver histology, less invasive measures with low intra- and inter-observer variability are needed. Measurement of liver stiffness shows promise; validated thresholds for staging AATLD are in development. Such advances will help patients by enabling risk stratification and personalised surveillance, along with streamlining the development process for novel therapies.
CONCLUSIONS: This inaugural forum generated a list of recommendations to address unmet needs in the field of AATLD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 59(2024), 10 vom: 01. Apr., Seite 1183-1195 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Loomba, Rohit [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alpha 1-Antitrypsin |
|---|
| Anmerkungen: |
Date Completed 23.04.2024 Date Revised 23.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.17967 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370063945 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370063945 | ||
| 003 | DE-627 | ||
| 005 | 20240424232051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240323s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.17967 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1385.xml |
| 035 | |a (DE-627)NLM370063945 | ||
| 035 | |a (NLM)38516814 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Loomba, Rohit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Review article |b New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.04.2024 | ||
| 500 | |a Date Revised 23.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Alpha-1 antitrypsin liver disease (AATLD) occurs in a subset of patients with alpha-1 antitrypsin deficiency. Risk factors for disease progression and specific pathophysiologic features are not well known and validated non-invasive assessments for disease severity are lacking. Currently, there are no approved treatments for AATLD | ||
| 520 | |a AIMS: To outline existing understanding of AATLD and to identify knowledge gaps critical to improving clinical trial design and development of new treatments | ||
| 520 | |a METHODS: This report was developed following a multi-stakeholder forum organised by the Alpha-1 Antitrypsin Deficiency Related Liver Disease Expert Panel in which experts presented an overview of the available literature on this topic | ||
| 520 | |a RESULTS: AATLD results from a 'gain of toxic function' and primarily manifests in those with the homozygous Pi*ZZ genotype. Accumulation of misfolded 'Z' AAT protein in liver cells triggers intracellular hepatocyte injury which may ultimately lead to hepatic fibrosis. Male gender, age over 50 years, persistently elevated liver tests, concomitant hepatitis B or C virus infection, and metabolic syndrome, including obesity and type 2 diabetes mellitus, are known risk factors for adult AATLD. While the gold standard for assessing AATLD disease activity is liver histology, less invasive measures with low intra- and inter-observer variability are needed. Measurement of liver stiffness shows promise; validated thresholds for staging AATLD are in development. Such advances will help patients by enabling risk stratification and personalised surveillance, along with streamlining the development process for novel therapies | ||
| 520 | |a CONCLUSIONS: This inaugural forum generated a list of recommendations to address unmet needs in the field of AATLD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a alpha 1-Antitrypsin |2 NLM | |
| 700 | 1 | |a Clark, Ginger |e verfasserin |4 aut | |
| 700 | 1 | |a Teckman, Jeff |e verfasserin |4 aut | |
| 700 | 1 | |a Ajmera, Veeral |e verfasserin |4 aut | |
| 700 | 1 | |a Behling, Cynthia |e verfasserin |4 aut | |
| 700 | 1 | |a Brantly, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Brenner, David |e verfasserin |4 aut | |
| 700 | 1 | |a D'Armiento, Jeanine |e verfasserin |4 aut | |
| 700 | 1 | |a Fried, Michael W |e verfasserin |4 aut | |
| 700 | 1 | |a Iyer, Janani S |e verfasserin |4 aut | |
| 700 | 1 | |a Mandorfer, Mattias |e verfasserin |4 aut | |
| 700 | 1 | |a Rockey, Don C |e verfasserin |4 aut | |
| 700 | 1 | |a Tincopa, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Vuppalanchi, Raj |e verfasserin |4 aut | |
| 700 | 1 | |a Younossi, Zobair |e verfasserin |4 aut | |
| 700 | 1 | |a Krag, Aleksander |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Alice M |e verfasserin |4 aut | |
| 700 | 1 | |a Strnad, Pavel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 59(2024), 10 vom: 01. Apr., Seite 1183-1195 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2024 |g number:10 |g day:01 |g month:04 |g pages:1183-1195 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.17967 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2024 |e 10 |b 01 |c 04 |h 1183-1195 | ||